Drug Profile
Acarbose/orlistat - Empros Pharma
Alternative Names: EMP-16-01; EMP-16-02Latest Information Update: 12 Oct 2023
Price :
$50
*
At a glance
- Originator Empros Pharma
- Class Anorectics; Antihyperlipidaemics; Carbohydrates; Lactones; Obesity therapies
- Mechanism of Action Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Obesity
Most Recent Events
- 22 Sep 2023 Empros Pharmaceuticals initiates phase I trial for Obesity (In Volunteers) in Sweden (PO) (NCT06013163) (EudraCT2023-505671-74-00)
- 01 Sep 2023 Empros Pharmaceuticals plans a phase I PK-PD trial for Obesity (In Volunteers)in Sweden (PO, Capsule) in September 2023 (NCT06013163) (EudraCT2023-505671-74-00)
- 14 Mar 2023 Empros Pharma initiates enrolment in a phase II trial for Obesity in Sweden (PO) (EudraCT2022-003320-40; EP003)